These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 22074425)

  • 81. An activatable prodrug for the treatment of metastatic tumors.
    Kim EJ; Bhuniya S; Lee H; Kim HM; Cheong C; Maiti S; Hong KS; Kim JS
    J Am Chem Soc; 2014 Oct; 136(39):13888-94. PubMed ID: 25238144
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.
    Bagshawe KD
    Expert Rev Anticancer Ther; 2006 Oct; 6(10):1421-31. PubMed ID: 17069527
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Gene-directed enzyme prodrug therapy (GDEPT)--recognizing the present limitations of gene therapy for the treatment of cancer.
    Knox RJ
    Curr Opin Investig Drugs; 2001 Jun; 2(6):835-8. PubMed ID: 11572666
    [No Abstract]   [Full Text] [Related]  

  • 84. Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds.
    Springer CJ; Bagshawe KD; Sharma SK; Searle F; Boden JA; Antoniw P; Burke PJ; Rogers GT; Sherwood RF; Melton RG
    Eur J Cancer; 1991; 27(11):1361-6. PubMed ID: 1835849
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Recent advances in small molecule prodrugs for cancer therapy.
    Wang P; Jin X; Cai J; Chen J; Ji M
    Anticancer Agents Med Chem; 2014 Mar; 14(3):418-39. PubMed ID: 23869777
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT).
    Springer CJ; Antoniw P; Bagshawe KD; Wilman DE
    Anticancer Drug Des; 1991 Nov; 6(5):467-79. PubMed ID: 1764165
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Prodrugs in photodynamic anticancer therapy.
    Musiol R; Serda M; Polanski J
    Curr Pharm Des; 2011; 17(32):3548-59. PubMed ID: 22074426
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Prodrugs for targeted cancer therapy.
    Souza C; Pellosi DS; Tedesco AC
    Expert Rev Anticancer Ther; 2019 Jun; 19(6):483-502. PubMed ID: 31055990
    [No Abstract]   [Full Text] [Related]  

  • 89. From bench to bedside for gene-directed enzyme prodrug therapy of cancer.
    Dachs GU; Tupper J; Tozer GM
    Anticancer Drugs; 2005 Apr; 16(4):349-59. PubMed ID: 15746571
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy.
    Senter PD
    FASEB J; 1990 Feb; 4(2):188-93. PubMed ID: 2404820
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo.
    Rogers GT; Burke PJ; Sharma SK; Koodie R; Boden JA
    Br J Cancer; 1995 Dec; 72(6):1357-63. PubMed ID: 8519645
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations.
    Syrigos KN; Epenetos AA
    Anticancer Res; 1999; 19(1A):605-13. PubMed ID: 10226606
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A.
    Prosser GA; Copp JN; Mowday AM; Guise CP; Syddall SP; Williams EM; Horvat CN; Swe PM; Ashoorzadeh A; Denny WA; Smaill JB; Patterson AV; Ackerley DF
    Biochem Pharmacol; 2013 Apr; 85(8):1091-103. PubMed ID: 23399641
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Cytochrome P450-based gene therapy for cancer treatment: from concept to the clinic.
    Jounaidi Y
    Curr Drug Metab; 2002 Dec; 3(6):609-22. PubMed ID: 12369889
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Metabolism-based anticancer drug design.
    Kwon CH
    Arch Pharm Res; 1999 Dec; 22(6):533-41. PubMed ID: 10615856
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Therapeutic Potential of Prodrugs Towards Targeted Drug Delivery.
    Mishra AP; Chandra S; Tiwari R; Srivastava A; Tiwari G
    Open Med Chem J; 2018; 12():111-123. PubMed ID: 30505359
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Development of pyrrolo[2,1-c][1,4]benzodiazepine beta-galactoside prodrugs for selective therapy of cancer by ADEPT and PMT.
    Kamal A; Tekumalla V; Krishnan A; Pal-Bhadra M; Bhadra U
    ChemMedChem; 2008 May; 3(5):794-802. PubMed ID: 18247436
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Monoclonal antibody-beta-lactamase conjugates for the activation of a cephalosporin mustard prodrug.
    Svensson HP; Kadow JF; Vrudhula VM; Wallace PM; Senter PD
    Bioconjug Chem; 1992; 3(2):176-81. PubMed ID: 1515470
    [TBL] [Abstract][Full Text] [Related]  

  • 99. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy.
    Alaoui AE; Saha N; Schmidt F; Monneret C; Florent JC
    Bioorg Med Chem; 2006 Jul; 14(14):5012-9. PubMed ID: 16554162
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Strategies on the development of small molecule anticancer drugs for targeted therapy.
    Lu YH; Gao XQ; Wu M; Zhang-Negrerie D; Gao Q
    Mini Rev Med Chem; 2011 Jun; 11(7):611-24. PubMed ID: 21699492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.